Antonio Laurenza
Chief Medical Officer - Interim @Zyvran Pharmaceuticals
Signup · Get unlimited contacts
WORK HISTORY
Chief Medical Officer - Interim @Zyvran Pharmaceuticals
Los Angeles, CA, US
Development of pre-clinical and clinical strategy and plans for pipeline assets, and execution toward IND filing for chronic peripheral pain. Preparation and attendance of pre-IND FDA meeting, meetings with CROs and CDMOs, and with potential investors.
EDUCATION
Università degli Studi di Napoli Federico II
MD
SKILLS
ABOUT ANTONIO LAURENZA
Physician-Scientist with expertise in Neurology and Psychiatry, and broad experience in internal medicine and pre-clinical disciplines. Seventeen years of preclinical research, including Fulbright Scholarship at FDA in Bethesda, MD, and Laboratory Headship at Glaxo Research Institute in Research Triangle Park, NC. My special skill is leading Phase I & II clinical, clinical operations, and operational teams in drug development strategies focused on small molecules, including antisense oligonucleotides, and biologics (gene therapy, mAbs, fusion proteins).Successes at TAKEDA PHARMACEUTICALS, EISAI, INC, and GSK include: REGULATORY SUBMISSIONS & APPROVALS: Background from pre-clinical to commercialization with significant direct global regulatory interactions. Delivered submissions and approvals as Global Project Leader, with key roles in 18 NDA/sNDA/MAAs, 3 MAAs, and 25+ INDs. Submitted/presented to regulators directly at multiple regulatory agencies. GLOBAL PROGRAM LEADER (Takeda): Directed programs with antisense oligonucleotides in rare diseases (Amyotrophic Lateral Sclerosis, Huntington\'s Disease, Spino-Cerebellar Atrophy type 3), and Myasthenia Gravis; gene therapy in Huntington\'s Disease, mAb in Multiple System Atrophy and Parkinson’s Disease; and small molecules in Parkinson’s Disease, Psychotic Disorders, Mood Disorders, and Substance Use Disorders. INTERNATIONAL PROJECT LEADER / CLINICAL DEVELOPMENT GROUP HEAD (Eisai): Head of epilepsy franchise in Clinical Development. Intl. Project Leader for perampanel, first-in-class AMPA antagonist with 80+ global submissions and launches for epilepsy in adults, adolescents, and pediatrics, and in Phase for Lennox-Gastaut Syndrome. PSYCHIATRY & NEUROLOGY PIPELINE (GSK): Oversaw clinical programs and served as clinical interface with Psychiatry Center of Excellence in Drug Discovery, including POC strategy across pipeline. Provided Phase II program leadership in multiple CNS disease areas, many new to company and with unprecedented MOAs. Clinical Leader of Phase program in Parkinson\'s Disease.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.